Back to School: How biopharma can reboot drug development. Access exclusive analysis here

T902611: TLRK said it discontinued development of T611 in order to focus its clinical efforts. The company said studies of T611, which was in Phase II testing f

Tularik Inc. (TLRK), South San Francisco, Calif.
Product:

Read the full 88 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE